<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20135" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cromolyn Sodium</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Minutello</surname>
            <given-names>Katrina</given-names>
          </name>
          <aff>Mclaren Oakland Coorporation</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Vikas</given-names>
          </name>
          <aff>Wellness Psychiatry P.C</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Katrina Minutello declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vikas Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20135.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Cromolyn sodium is a mast cell stabilizer derived from khellin, a natural extract from the herb <italic toggle="yes">Ammi visnaga,</italic>&#x000a0;first introduced as an inhaled treatment for asthma in 1969. Cromolyn sodium prevents the release of inflammatory mediators like histamine and leukotrienes, helping to manage asthma, allergic rhinitis, mastocytosis, and certain allergic eye conditions. In some patients, cromolyn sodium&#x000a0;improves symptoms of diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients. This medication is not effective for acute asthma attacks but is used prophylactically. Available in various forms, including oral, nasal, and ophthalmic solutions, cromolyn sodium is FDA-approved for asthma prophylaxis, allergic rhinitis, and mast cell diseases, with off-label uses for food allergies and inflammatory bowel disease.&#x000a0;This activity for healthcare professionals is designed to enhance the learner's competence in prescribing cromolyn sodium effectively and implementing an appropriate interprofessional management approach in patients treated with this medication to improve outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Differentiate cromolyn sodium from other asthma and allergy treatments, understanding its unique mechanism as a mast cell stabilizer.</p></list-item><list-item><p>Screen for potential allergic or adverse reactions associated with cromolyn sodium to ensure safe and effective treatment.</p></list-item><list-item><p>Implement evidence-based guidelines for the prophylactic use of cromolyn sodium in patients with asthma and mast cell disorders.</p></list-item><list-item><p>Apply interprofessional team strategies to improve care coordination and outcomes in patients treated with&#x000a0;cromolyn sodium.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20135&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20135">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20135.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>Historical Uses of&#x000a0;Cromolyn Sodium</bold>
</p>
        <p>Cromolyn sodium was derived from furanochromone, or khellin, a natural drug product extracted from the eastern Mediterranean herb&#x000a0;<italic toggle="yes">Ammi visnaga</italic>. The key active constituents of khellin were chromones; some of these chromones could delay the onset of bronchial antigen-induced&#x000a0;distress in guinea pigs. In 1965, researcher&#x000a0;Roger Altounyan, who had asthma, discovered cromolyn sodium; he showed that the inhalation of cromolyn sodium taken before an asthmatic attack could attenuate asthmatic symptoms.</p>
        <p>Later, in 1969, the first inhaled cromolyn sodium was launched in the United Kingdom to treat asthma in children and adults. Researchers demonstrated the effectiveness of cromolyn sodium against exercise-induced asthma and the&#x000a0;nasal application against antigen challenge in the nose at&#x000a0;the Royal Society of Medicine&#x000a0;symposium in 1969. Several reports were published in the early 1970s on the use of topical solutions of cromolyn in eye diseases, which later led to the discovery of the important benefit of cromolyn sodium for treating vernal keratoconjunctivitis.<xref ref-type="bibr" rid="article-20135.r1">[1]</xref><xref ref-type="bibr" rid="article-20135.r2">[2]</xref></p>
        <p>
<bold>United States Food and Drug Administration-Approved Indications of&#x000a0;Cromolyn Sodium</bold>
</p>
        <p>Cromolyn sodium is not immediate-acting and has no direct bronchodilator effects. Therefore, clinicians should not treat acute asthma attacks with this medication. However, cromolyn sodium is a United States Food and Drug Administration (FDA)-approved medication for the following indications:</p>
        <list list-type="bullet">
          <list-item>
            <p>Prophylaxis of mild to moderate bronchial asthma and adjunctive treatment of allergic rhinitis and systemic mast cell disease (ie, mastocytosis) in pediatric patients and adults&#x000a0;<xref ref-type="bibr" rid="article-20135.r3">[3]</xref><xref ref-type="bibr" rid="article-20135.r4">[4]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients using oral solutions (concentrate)&#x000a0;<xref ref-type="bibr" rid="article-20135.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Ophthalmic solution for the symptomatic treatment of certain allergic eye conditions, eg, vernal conjunctivitis, keratitis, and keratoconjunctivitis&#x000a0;<xref ref-type="bibr" rid="article-20135.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>To prevent and relieve nasal symptoms of hay fever and other nasal allergies, including runny or itchy nose, sneezing, and allergic stuffy nose, using the metered spray formulation&#x000a0;<xref ref-type="bibr" rid="article-20135.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses of&#x000a0;Cromolyn Sodium</bold>
</p>
        <p>Cromolyn sodium may be used off-labeled for the following indications:</p>
        <list list-type="bullet">
          <list-item>
            <p>Prevent severe adverse reactions to foods&#x000a0;<xref ref-type="bibr" rid="article-20135.r8">[8]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Manage inflammatory bowel disease&#x000a0;<xref ref-type="bibr" rid="article-20135.r9">[9]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Treat superior limbic keratoconjunctivitis&#x000a0;<xref ref-type="bibr" rid="article-20135.r10">[10]</xref><xref ref-type="bibr" rid="article-20135.r11">[11]</xref><xref ref-type="bibr" rid="article-20135.r12">[12]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20135.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Cromolyn sodium is a mast cell stabilizer that prevents the subsequent release of inflammatory mediators, including histamine and leukotrienes, which cause allergic symptoms and bronchoconstriction.<xref ref-type="bibr" rid="article-20135.r13">[13]</xref><xref ref-type="bibr" rid="article-20135.r14">[14]</xref>&#x000a0;This treatment inhibits mast cell degranulation, normally implicated in anaphylaxis following exposure to reactive allergens. Cromolyn sodium differs from antihistamine medications, which reduce the action of histamines following the release from mast cells. Unlike corticosteroids that inhibit the late response of antigen-induced asthmatic reactions, cromolyn sodium inhibits immediate and late reactions.<xref ref-type="bibr" rid="article-20135.r15">[15]</xref><xref ref-type="bibr" rid="article-20135.r12">[12]</xref>&#x000a0;Additionally, cromolyn sodium has been associated with improvement in flushing, headaches, diarrhea, vomiting, nausea, urticaria, abdominal pain, and itching in patients with mastocytosis.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>Cromolyn sodium is absorbed poorly via oral solution and has a delayed onset of action of 2&#x000a0;to 6 weeks after initiation. Similarly, less than 0.07% of administered&#x000a0;cromolyn sodium is absorbed from ophthalmic solution or drops. The effect of cromolyn sodium on mast cells lasts approximately 6 hours&#x000a0;following administration. The bioavailability of cromolyn sodium is 0.5% to 2%, with a half-life of 80&#x000a0;to 90 minutes. Cromolyn sodium is&#x000a0;primarily&#x000a0;excreted (98%) in the feces unabsorbed, with the remainder excreted in the urine.</p>
      </sec>
      <sec id="article-20135.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Cromolyn Sodium Dosage Forms and Strengths</bold>
</p>
        <p>The following dosage forms are recommended for cromolyn sodium:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Oral solution</bold>: 100 mg/5 mL ampule</p>
          </list-item>
          <list-item>
            <p><bold>Nasal spray</bold>: 5.2 mg/1 actuation</p>
          </list-item>
          <list-item>
            <p><bold>Ophthalmic solution</bold>: 4% (10 mL)</p>
          </list-item>
          <list-item>
            <p><bold>Inhalation solution</bold>: 10 mg/1 mL, 20 mg/2mL nebulization vial</p>
          </list-item>
        </list>
        <p>
<bold>Recommended Dosages for FDA-Approved Indications</bold>
</p>
        <p>&#x000a0;The following dosage formulations for each indication are recommended for cromolyn sodium:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Asthma prophylaxis</bold>&#x000a0;
<list list-type="bullet"><list-item><p><bold>Metered-dose inhaler</bold>: 2 oral inhalations (800 &#x000b5;g/spray) 4 times daily at regular intervals; may need to titrate</p></list-item><list-item><p><bold>Nebulizer</bold>: 20 mg (1 vial) via nebulization 4 times daily at regular intervals
<list list-type="bullet"><list-item><p><bold>Reactive bronchoconstriction</bold>: In patients who develop acute bronchoconstriction when exposed to environmental pollutants, toluene diisocyanate, and in response to exercise, cromolyn sodium should be administered shortly before exposure to the precipitating factor.</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Mastocytosis</bold> (systemic)&#x000a0;
<list list-type="bullet"><list-item><p><bold>Oral solution</bold>: Empty ampules into a glass of water and drink 30 minutes before meals and bedtime
<list list-type="bullet"><list-item><p><bold>Children older than 12 years and adults</bold>: Cromolyn sodium solution 200 mg by mouth 4 times daily, 30 minutes before meals and bedtime; may increase to 40 mg/kg/day if symptoms remain uncontrolled for 2&#x000a0;to 3 weeks</p></list-item><list-item><p><bold>Children younger than 2 years</bold>: Safety and efficacy not established</p></list-item><list-item><p><bold>Children aged 2 to 12 years</bold>: Cromolyn sodium solution 100 mg orally 4 times daily, 30 minutes before meals and at bedtime; not to exceed 40 mg/kg/day</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Allergic rhinitis</bold>
<list list-type="bullet"><list-item><p><bold>Nasal inhalation</bold>: One spray/nostril 3&#x000a0;to 6 times daily</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Keratitis, vernal conjunctivitis, and vernal keratoconjunctivitis</bold>
<list list-type="bullet"><list-item><p><bold>Ophthalmic solution</bold>: Children older than 4&#x000a0;years old, 1 to 2 drops in each eye 4&#x000a0;to 6 times daily, at regular intervals</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Dosages of&#x000a0;Cromolyn Sodium</bold>
</p>
        <p>Cromolyn sodium oral solution may be used for food allergy and irritable bowel syndrome using the following dosages based on the patient's age:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Children older than 12 years and adults</bold>: Cromolyn sodium solution 200 mg by mouth 4 times daily; may double dose if inadequate symptom control within 2&#x000a0;to 3 weeks with a maximum dosage of 400 mg orally 4 times daily</p>
          </list-item>
          <list-item>
            <p><bold>Children younger than 2 years</bold>: Not recommended</p>
          </list-item>
          <list-item>
            <p><bold>Children aged 2 to 12 years</bold>: Cromolyn sodium solution 100 mg orally 4 times daily initially, may increase as indicated to a maximum dosage of 40 mg/kg/day</p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p>For the following special populations, management considerations regarding cromolyn sodium include:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Renal impairment</bold>: The manufacturer's labeling does not recommend specific dosage adjustments for patients with renal impairment. However, the recommended dosage for cromolyn oral solution should be decreased in patients with reduced renal function.</p>
          </list-item>
          <list-item>
            <p><bold>Hepatic impairment</bold>:&#x000a0;The manufacturer's labeling does not recommend a specific dosage adjustment for patients with hepatic impairment. However, the recommended dosage for cromolyn oral&#x000a0;should be decreased in patients with reduced&#x000a0;hepatic function.</p>
          </list-item>
          <list-item>
            <p><bold>Pregnancy</bold>: Cromolyn sodium is pregnancy category B, though risk has not been entirely ruled out. As per manufacturer labels,&#x000a0;subcutaneous doses up to 540 mg/kg in mice similar to the maximum recommended daily oral dosage in adults), 164 mg/kg in rats (oral dosage less than the maximum recommended daily dosage in adults), or intravenous doses up to 485 mg/kg in rabbits (4 times the maximum recommended oral dosage in adults) produced no evidence of fetal malformations. As per the Global Initiative for Asthma 2023 guidelines, other therapies with better efficacy are available and should be recommended as treatment for asthma while pregnant.<xref ref-type="bibr" rid="article-20135.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Breastfeeding</bold>: The amount of cromolyn sodium excreted in breast milk is unknown.<xref ref-type="bibr" rid="article-20135.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Pediatric</bold>:&#x000a0;According to available clinical data, the dose should not exceed 20 mg/kg/day for infants up to 6 months of age.<xref ref-type="bibr" rid="article-20135.r18">[18]</xref>&#x000a0;A risk-benefit analysis should be performed before using this product in pediatric patients younger than 2&#x000a0;years of age.</p>
          </list-item>
          <list-item>
            <p><bold>Older individuals</bold>: The safety and efficacy of&#x000a0;cromolyn sodium have not been systematically studied in older adults. However, due to the greater&#x000a0;probability of decreased hepatic, renal, or cardiac functions, concomitant disease, or other drug therapy in this patient population, cromolyn sodium treatment should usually be initiated at the lowest dosage range.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20135.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The frequency of adverse events in patients using cromolyn sodium remains unclear.&#x000a0;Adverse events also vary depending on the administration route.<xref ref-type="bibr" rid="article-20135.r19">[19]</xref>&#x000a0;The ophthalmic solution is associated with transient eye burning upon administration, and eye dryness, puffiness, irritation, itchiness, rash, and styes may be seen. Adverse events reported with the cromolyn sodium nasal spray were nasal congestion, sneezing, nasal itching, nosebleeds, rhinoconjunctivitis, and headaches. Adverse events reported with the inhalation solution were throat irritation and hoarseness, esophagitis, laryngeal and pharyngeal edema, drowsiness, dizziness, bronchial irritation, pulmonary infiltrates, and cough.<xref ref-type="bibr" rid="article-20135.r20">[20]</xref></p>
        <p>Most of the adverse events reported in patients with mastocytosis have been transient and can be symptoms of the disease. The most frequently reported adverse events in patients with mastocytosis who received oral cromolyn sodium solution in clinical studies were headache, diarrhea, pruritus, nausea, myalgia, abdominal pain, rash, and irritability. In addition, adverse events associated with oral solution include vomiting, constipation, erythema, photosensitivity, urticaria, and angioedema. Other reported adverse events, including&#x000a0;reports of dyspepsia,&#x000a0;constipation, glossitis, flatulence, stomatitis, vomiting, dysphagia, and esophagospasm, in clinical studies of patients with comorbid conditions as well as postmarketing patient experience were infrequent; attribution to cromolyn could not be determined.</p>
      </sec>
      <sec id="article-20135.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Absolute Contraindications</bold>
</p>
        <p>Hypersensitivity to cromolyn products or components of the formulation is the absolute&#x000a0;contraindication for cromolyn sodium.&#x000a0;</p>
        <p>
<bold>Cromolyn Sodium Precautions</bold>
</p>
        <p>Clinicians should consider the following cautions in the management of cromolyn sodium:</p>
        <list list-type="bullet">
          <list-item>
            <p>Bronchospasm may occur with a cough after inhalation; if this happens, manage using a fast-acting bronchodilator.</p>
          </list-item>
          <list-item>
            <p>Cromolyn inhalation solution should not be used in status asthmaticus.</p>
          </list-item>
          <list-item>
            <p>Caution should be exercised when withdrawing cromolyn inhalation solution use or tapering the dosage as symptoms may reoccur.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20135.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Symptomatic improvement should be assessed&#x000a0;via pulmonary function tests for individuals diagnosed with bronchial asthma. Symptoms may reoccur when tapering or withdrawing cromolyn sodium. Since&#x000a0;it is preventive medicine, cromolyn sodium may take up to 4 weeks for the patient to experience maximum benefit.&#x000a0;Patients with a history of cardiac arrhythmias or coronary artery disease using inhalation solution should undergo cardiac follow-up due to the contents of metered-dose inhaler propellants.</p>
        <p>The clinician should closely monitor kidney and liver function in patients with hepatic or renal insufficiency and begin with a reduced dose when considering treatment with cromolyn sodium. The medication's effects may increase in patients with these medical conditions, thus increasing the chance of adverse effects. Regular eye examinations are necessary when using cromolyn sodium ophthalmic solution.</p>
      </sec>
      <sec id="article-20135.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Cromolyn sodium is poorly absorbed and is low in toxicity. No severe toxicity reactions have been reported, and a specific toxic dose has not been established. Research verifying the efficacy or safety of cromolyn sodium is insufficient regarding use in pediatric patients younger than 2&#x000a0;years. However, acute life-threatening reactions have been reported.&#x000a0;</p>
        <p>In the event of a hypersensitivity reaction, patients should receive treatment with antihistamines with or without beta-agonists, corticosteroids, and epinephrine. In the case of a severe hypersensitivity reaction, oxygen, antihistamines, epinephrine, corticosteroids, electroencephalogram monitoring, and intravenous fluids should be administered. No specific labs or testing are necessary unless indicated.<xref ref-type="bibr" rid="article-20135.r21">[21]</xref><xref ref-type="bibr" rid="article-20135.r22">[22]</xref>&#x000a0;Management of mild to moderate toxicity is symptomatic and supportive. The clinician should correct&#x000a0;any significant fluid and electrolyte abnormalities in patients with vomiting or diarrhea. Severe toxicity is not expected following an overdose, which should be managed with symptomatic and supportive treatment.</p>
      </sec>
      <sec id="article-20135.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The management of cromolyn sodium therapy requires a coordinated, interprofessional approach involving physicians, advanced practitioners, nurses, pharmacists, and other healthcare professionals to ensure patient-centered care, improved outcomes, and patient safety. Cromolyn sodium is available in various forms and should be administered at regular intervals for optimal efficacy. Clinicians should follow the Global Initiative for Asthma 2023 guidelines, which suggest that while cromolyn is FDA-approved for asthma, it is less effective than other therapies and is not recommended for routine use.</p>
        <p>Even though these are rare, effective communication between healthcare professionals is crucial in monitoring and managing potential adverse events or hypersensitivity reactions. Nurses and pharmacists must be vigilant in recognizing any adverse events and collaborate with the clinical team to manage them. In a severe reaction, the healthcare team must quickly withdraw cromolyn, administer emergency treatments like epinephrine, oxygen, antihistamines, and corticosteroids, and ensure continuous patient monitoring. A pharmacist should review the patient&#x02019;s medication records to avoid future complications, while the intensivist may be consulted for hospital observation. After a hypersensitivity event, clinicians must discuss alternative therapies with the patient. This interprofessional coordination enhances patient safety and team performance in cromolyn sodium management for asthma, allergic rhinitis, and mastocytosis.</p>
      </sec>
      <sec id="article-20135.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20135&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20135">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20135/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20135">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20135.s11">
        <title>References</title>
        <ref id="article-20135.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edwards</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>The discovery of cromolyn sodium and its effect on research and practice in allergy and immunology.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>115</volume>
            <issue>4</issue>
            <fpage>885</fpage>
            <page-range>885-8</page-range>
            <pub-id pub-id-type="pmid">15806020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20135.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernstein</surname>
                <given-names>IL</given-names>
              </name>
            </person-group>
            <article-title>Cromolyn sodium.</article-title>
            <source>Chest</source>
            <year>1985</year>
            <month>Jan</month>
            <volume>87</volume>
            <issue>1 Suppl</issue>
            <fpage>68S</fpage>
            <page-range>68S-73S</page-range>
            <pub-id pub-id-type="pmid">3917246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20135.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kramer</surname>
                <given-names>ON</given-names>
              </name>
              <name>
                <surname>Barkoff</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Mast Cell Activation Syndrome.</article-title>
            <source>Skinmed</source>
            <year>2017</year>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>477</fpage>
            <page-range>477-479</page-range>
            <pub-id pub-id-type="pmid">29282192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20135.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tefferi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pardanani</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Systemic mastocytosis: current concepts and treatment advances.</article-title>
            <source>Curr Hematol Rep</source>
            <year>2004</year>
            <month>May</month>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>197</fpage>
            <page-range>197-202</page-range>
            <pub-id pub-id-type="pmid">15087068</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20135.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pontasch</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Bradford</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Oral agents in the management of urticaria: patient perception of effectiveness and level of satisfaction with treatment.</article-title>
            <source>Ann Pharmacother</source>
            <year>1993</year>
            <month>Jun</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>730</fpage>
            <page-range>730-1</page-range>
            <pub-id pub-id-type="pmid">8329794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20135.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ben-Eli</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Topical antihistamines, mast cell stabilizers, and dual-action agents in ocular allergy: current trends.</article-title>
            <source>Curr Opin Allergy Clin Immunol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>411</fpage>
            <page-range>411-416</page-range>
            <pub-id pub-id-type="pmid">30020258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20135.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frostad</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>The treatment of seasonal allergic rhinitis with a 2% aqueous solution of sodium cromoglycate delivered by a metered dose nasal spray.</article-title>
            <source>Clin Allergy</source>
            <year>1977</year>
            <month>Jul</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>347</fpage>
            <page-range>347-53</page-range>
            <pub-id pub-id-type="pmid">412610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20135.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kjellman</surname>
                <given-names>NI</given-names>
              </name>
            </person-group>
            <article-title>Food allergy--treatment and prevention.</article-title>
            <source>Ann Allergy</source>
            <year>1987</year>
            <month>Nov</month>
            <volume>59</volume>
            <issue>5 Pt 2</issue>
            <fpage>168</fpage>
            <page-range>168-74</page-range>
            <pub-id pub-id-type="pmid">3120629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20135.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singleton</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Medical therapy of inflammatory bowel disease.</article-title>
            <source>Med Clin North Am</source>
            <year>1980</year>
            <month>Nov</month>
            <volume>64</volume>
            <issue>6</issue>
            <fpage>1117</fpage>
            <page-range>1117-33</page-range>
            <pub-id pub-id-type="pmid">6109796</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20135.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <article-title>OTC drugs for seasonal allergies.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2019</year>
            <month>Apr</month>
            <day>22</day>
            <volume>61</volume>
            <issue>1570</issue>
            <fpage>57</fpage>
            <page-range>57-60</page-range>
            <pub-id pub-id-type="pmid">31169808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20135.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castells</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Butterfield</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management.</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>1097</fpage>
            <page-range>1097-1106</page-range>
            <pub-id pub-id-type="pmid">30961835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20135.r12">
          <label>12</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hashmi</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Chakraborty</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <chapter-title>Asthma Medications</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">30285350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20135.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuzubova</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Lebedeva</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Dvorakovskaya</surname>
                <given-names>IV</given-names>
              </name>
              <name>
                <surname>Preobrazhenskaya</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Surkova</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Titova</surname>
                <given-names>ON</given-names>
              </name>
            </person-group>
            <article-title>[EFFECT OF MAST CELL DEGRANULATION BLOCKADE ON THE INFLAMMATION OUTCOME IN THE MODEL OF OBSTRUCTIVE LUNG PATHOLOGY].</article-title>
            <source>Ross Fiziol Zh Im I M Sechenova</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>102</volume>
            <issue>7</issue>
            <fpage>825</fpage>
            <page-range>825-32</page-range>
            <pub-id pub-id-type="pmid">30193050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20135.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuzubova</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Fedin</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Lebedeva</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Titova</surname>
                <given-names>ON</given-names>
              </name>
            </person-group>
            <article-title>[ROLE OF MAST CELLS IN BRONCHIAL CONTRACTION IN NONALLERGIC OBSTRUCTIVE LUNG PATHOLOGY].</article-title>
            <source>Ross Fiziol Zh Im I M Sechenova</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>103</volume>
            <issue>2</issue>
            <fpage>193</fpage>
            <page-range>193-200</page-range>
            <pub-id pub-id-type="pmid">30199200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20135.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murphy</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Wandalsen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Larenas-Linnemann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>El Beleidy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zaytseva</surname>
                <given-names>OV</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Nebulized Inhaled Corticosteroids in Asthma Treatment in Children 5 Years or Younger: A Systematic Review and Global Expert Analysis.</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>1815</fpage>
            <page-range>1815-1827</page-range>
            <pub-id pub-id-type="pmid">32006721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20135.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Venkatesan</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>2023 GINA report for asthma.</article-title>
            <source>Lancet Respir Med</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>11</volume>
            <issue>7</issue>
            <fpage>589</fpage>
            <pub-id pub-id-type="pmid">37302397</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20135.r17">
          <label>17</label>
          <element-citation publication-type="book">
            <chapter-title>Cromolyn</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>5</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20135.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ng</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ohlsson</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cromolyn sodium for the prevention of chronic lung disease in preterm infants.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>Jan</month>
            <day>23</day>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>CD003059</fpage>
            <pub-id pub-id-type="pmid">28114736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20135.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clift</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Holzel</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Long-term therapy with sodium cromoglycate (intal, lomudal or aarane): effects and side effects.</article-title>
            <source>Ann Allergy</source>
            <year>1978</year>
            <month>Nov</month>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>313</fpage>
            <page-range>313-8</page-range>
            <pub-id pub-id-type="pmid">102223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20135.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shapiro</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>K&#x000f6;nig</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Cromolyn sodium: a review.</article-title>
            <source>Pharmacotherapy</source>
            <year>1985</year>
            <season>May-Jun</season>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>156</fpage>
            <page-range>156-70</page-range>
            <pub-id pub-id-type="pmid">3927266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20135.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmad</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cromolyn sodium and anaphylaxis.</article-title>
            <source>Ann Intern Med</source>
            <year>1983</year>
            <month>Dec</month>
            <volume>99</volume>
            <issue>6</issue>
            <fpage>882</fpage>
            <pub-id pub-id-type="pmid">6418048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20135.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shearer</surname>
                <given-names>WT</given-names>
              </name>
            </person-group>
            <article-title>Anaphylaxis to disodium cromoglycate.</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>1996</year>
            <month>Sep</month>
            <volume>77</volume>
            <issue>3</issue>
            <fpage>165</fpage>
            <pub-id pub-id-type="pmid">8814038</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
